Escitalopram treatment in patients with MNCD-AD and ScVMNCD led to an increase in plasma BDNF concentrations and, as a result, to a decrease of cognitive deficits, as well as to a decrease of depressive and anxiety symptom severity. This evidence concerns the gene BDNF and Anxiety.